Study of the Safety and Efficacy of STI-6129 in Patients With Relapsed or Refractory Systemic AL Amyloidosis
NCT ID: NCT04316442
Last Updated: 2023-01-17
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE1/PHASE2
60 participants
INTERVENTIONAL
2021-04-01
2024-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The patients that will be treated with STI-6129 in this trial are relapsed or refractory systemic AL amyloidosis patients who have received prior lines of treatment.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study of Chimeric Fibril-Reactive Monoclonal Antibody 11-1F4 in Patients With AL Amyloidosis
NCT02245867
S1702 Isatuximab in Treating Patients With Relapsed or Refractory Primary Amyloidosis
NCT03499808
Isatuximab and Bendamustine in Systemic Light Chain Amyloidosis
NCT04943302
S9628 Dexamethasone Plus Interferon Alfa in Treating Patients With Primary Systemic Amyloidosis
NCT00002849
AL Amyloidosis and Anti-CD38-Daratunumab
NCT06571864
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Each patient enrolled will receive up to three 4-week cycles of STI-6129, unless a longer intermission is required. After the treatment period, patients will be monitored for up to a year.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
STI-6129 infusion
Intravenous infusion to be given with prophylaxis for infusion reactions if necessary.
STI-6129
Four cycles of intravenous infusion of STI-6129 will be given (one infusion every four weeks).
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
STI-6129
Four cycles of intravenous infusion of STI-6129 will be given (one infusion every four weeks).
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* The presence of a monoclonal light chain protein in serum
* Relapsed or refractory AL amyloidosis is defined as patients who have received ≥ 2 lines of treatment. Patients must have received at least one proteasome inhibitor during their prior therapy. Patients who have received prior daratumumab treatment or prior stem cell transplantation remain eligible. Patients may have relapsed with disease progression or have been refractory to their last prior line of treatment. Progression of disease that develops \> 60 days after the last dose of a treatment regimen in a patient who achieved at least a partial response (PR) defines a relapse. Refractory systemic AL amyloidosis is defined as the development of disease progression during therapy with an anti-AL amyloidosis treatment regimen or within 60 days of the last dose of an anti-AL amyloidosis treatment regimen or the achievement of less than a PR after ≥ 2 cycles
* Measurable disease defined as the finding by serum-free light chain (FLC) assay that the difference between the involved and uninvolved FLC (dFLC) is ≥ 50 mg/L
* Pulse oximetry ≥ 92% on room air
* ECOG performance status of 0, 1, or 2
* Willing to comply with the study schedule and all other protocol requirements
* Females of childbearing potential (FCBP) must have 2 negative pregnancy tests prior to treatment. All heterosexually active FCBP and all heterosexually active male patients must agree to use effective methods of birth control throughout the study
Exclusion Criteria
* Presence of non-AL amyloidosis
* A diagnosis of multiple myeloma
* A diagnosis of other malignancies if the malignancy has required therapy within the last 3 years or is not in complete remission. Exceptions are non-metastatic basal cell or squamous cell carcinomas of the skin or prostate cancer that does not require treatment
* Treatment with an allogeneic hematopoietic stem cell transplantation (HSCT) within 6 months prior to the planned infusion of STI-6129, or active graft-versus-host disease (GVHD) following the allogeneic transplant, or a requirement for currently receiving immunosuppressive therapy following the allogeneic transplant
* Revised Mayo Clinic AL amyloidosis stage \> 3
* New York Heart Association (NYHA) class \> 2
* Left ventricular ejection fraction (LVEF) \< 40%
* Patients with mean left ventricular wall thickness ≥ 12 mm and/or intraventricular septal thickness \> 25 mm by echocardiogram in the absence of hypertension or valvular heart disease
* Patients with NT-proBNP ≥ 1800 ng/L or BNP ≥ 400 ng/L, or cTNT ≥ 0.025 μg/L will be excluded in the dose-escalation stage of the study and can only be included in the PK and expansion stages after evaluation by cardiology and discussion with the principle investigator regarding the risk associated with the treatment
* Abnormal baseline hematological laboratory results at Screening:
* Hemoglobin \< 8.0 g/dL
* Platelet count \< 50,000/μL
* Absolute neutrophil count (ANC) \< 1000/μL
* Abnormal baseline chemistry laboratory results at Screening:
* Serum creatinine ≥ 2.0 mg/dL or estimated creatinine clearance \< 60 mL/min (using the Cockcroft-Gault equation)
* Serum aspartate aminotransferase (AST) or alanine aminotransferase (ALT) \> 3x the upper limit of normal (ULN) or serum total bilirubin \> 1.5x ULN (except for patients in whom hyperbilirubinemia is attributed to Gilbert's Syndrome)
* INR or aPTT \> 1.5x ULN within 1 week prior to the infusion of STI-6129, unless on a stable dose of an anticoagulant
* Pregnant or breastfeeding
* Active bacterial, viral, or fungal infection within 72 hours of the infusion of STI-6129; patients with ongoing use of prophylactic antibiotics, antifungal agents, or antiviral agents remain eligible as long as there is no evidence of active infection
* Have human immunodeficiency virus (HIV) infection, human T-cell leukemia virus type 1 (HTLV1) infection, or hepatitis B virus (HBV) or hepatitis C virus (HCV) viremia or are at risk for HBV reactivation (at risk for HBV reactivation is defined as being HBs antigen positive, or anti-HBc-antibody positive), or are positive for HBV deoxyribonucleic acid (DNA). HCV ribonucleic acid (RNA) must be undetectable by laboratory test
* QTcF \> 470 msec on a baseline ECG
* Any condition including the presence of laboratory abnormalities that places the patient at unacceptable risk if the patient was to participate in the study
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Sorrento Therapeutics, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Vaishali Sanchorawala, MD
Role: PRINCIPAL_INVESTIGATOR
Boston Medical Center
Michael Rosenzweig, MD
Role: PRINCIPAL_INVESTIGATOR
City of Hope National Medical Center
Jeffrey Zonder, MD
Role: PRINCIPAL_INVESTIGATOR
Barbara Ann Karmanos Cancer Institute Wertz Clinic
Anita D'Souza, MD
Role: PRINCIPAL_INVESTIGATOR
Froedtert Hospital & the Medical College of Wisconsin
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
City of Hope National Medical Center
Duarte, California, United States
Boston Medical Center
Boston, Massachusetts, United States
Barbara Ann Karmanos Cancer Institute Wertz Clinic
Detroit, Michigan, United States
Froedtert Hospital & the Medical College of Wisconsin
Milwaukee, Wisconsin, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
STI-6129-001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.